Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 931 to 945 of 1251 results for public health guidance

  1. SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)

    Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.

    HealthTech guidance
    Last updated
    19 February 2020

    Sections for HTG400

  2. Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

    In development Reference number: GID-HST10037 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  3. Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

    Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.

    Technology appraisal guidance
    Published
    25 June 2014
    View recommendations

    Sections for TA315

  4. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    Discontinued Reference number: GID-TA11277

    Technology appraisal guidance
    Discontinued

  5. Superior rectal artery embolisation for haemorrhoids

    Discontinued Reference number: GID-IPG10417

    Interventional procedures guidance
    Discontinued

  6. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development Reference number: GID-TA10900 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (HTG690)

    Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care.

    HealthTech guidance
    Published
    24 August 2023
    View recommendations

    Sections for HTG690

  8. Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

    Discontinued Reference number: GID-TA10164

    Technology appraisal guidance
    Discontinued

  9. Workplace health for employees with disabilities and long-term conditions

    Discontinued Reference number: GID-PHG58

    NICE guideline
    Discontinued

  10. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    Discontinued Reference number: GID-TA10596

    Technology appraisal guidance
    Discontinued

  11. Molecular testing strategies for Lynch syndrome in people with colorectal cancer (HTG430)

    Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer.

    HealthTech guidance
    Published
    22 February 2017
    View recommendations

    Sections for HTG430

  12. Digital technologies for multidisciplinary weight management

    In development Reference number: GID-HTE10077 Expected publication date: TBC

    Health technology evaluations
    In development

  13. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued Reference number: GID-TAG393

    Technology appraisal guidance
    Discontinued

  14. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued Reference number: GID-TAG526

    Technology appraisal guidance
    Discontinued

  15. Ovarian cancer: identifying and managing familial and genetic risk (NG241)

    This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.

    NICE guideline
    Published
    21 March 2024
    View recommendations

    Sections for NG241